Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Safety of Subcutaneous MOA-728 for Opioid-Induced Constipation
NCT00804141Phase 3Completed
- Sponsor
- Valeant Pharmaceuticals
- Start
- Dec 2008
- Primary completion
- Sep 2010
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 3 trial of methylnaltrexone in opioid-induced constipation (OIC), sponsored by Valeant Pharmaceuticals. Started Dec 2008; status: completed.
02
Drugs
methylnaltrexone
03
Conditions
opioid-induced constipation (OIC)
Beyond the preview
Go deeper on NCT00804141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00804141.